India  

Covaxin Phase 2&3 trials to resume in US after USFDA lifts clinical hold

IndiaTimes Monday, 23 May 2022
The US Food and Drug Administration (USFDA) has lifted the clinical hold on the Phase 2 and 3 immuno-bridging clinical trials of Bharat Biotech’s Covid-19 vaccine Covaxin that were being conducted in the US, said Ocugen, the Hyderabad-based vaccine maker’s partner for US, Canada and Mexico, on Monday.
0
shares
ShareTweetSavePostSend
 

You Might Like


💡 newsR Knowledge: Other News Mentions

Food and Drug Administration Food and Drug Administration Agency of the US Department of Health and Human Services

FDA Calls for Fall COVID Boosters To Target Omicron Subvariants [Video]

FDA Calls for Fall COVID Boosters To Target Omicron Subvariants

FDA Calls for Fall COVID Boosters , To Target Omicron Subvariants. NBC News reports that on June 30, the Food and Drug Administration asked vaccine makers to modify upcoming booster shots to target subvariants of Omicron. The Omicron subvariants the agency wishes to target are BA.4 and BA.5. Officials have called on vaccine makers Pfizer-BioNTech and Moderna to produce bivalent vaccines, . which are intended to target the original strain of COVID-19 as well as its subvariants. As we move into the fall and winter, it is critical that we have safe and effective vaccine boosters that can provide protection... , Dr. Peter Marks, FDA, via NBC News. ... against circulating and emerging variants to prevent the most severe consequences of COVID-19. , Dr. Peter Marks, FDA, via NBC News. As of the week ending June 25, Omicron subvariants BA.4 and BA.5 were responsible for 52% of all new cases of COVID-19. Per the Centers for Disease Control and Prevention, BA.1, the first variant of Omicron, caused 0% of new cases. Pfizer and Moderna have thus far altered vaccines to target the original strain of COVID-19 and BA.1. which increased the immune response to earlier iterations, though both have waned in their efficacy against BA.4 and BA.5

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer Says Updated COVID-19 Shot Effective Against Omicron [Video]

Pfizer Says Updated COVID-19 Shot Effective Against Omicron

Pfizer Says Updated COVID-19 Shot , Effective Against Omicron. NBC News reports Pfizer announced on June 25 that its updated coronavirus vaccine better targets the omicron variant. Experts say while current vaccines offer ample protection against new variants, . their effectiveness has waned in the age of omicron. The Food and Drug Administration has considered ordering altered vaccines, . hoping a modified recipe could offer more protection when coronavirus surges again this fall and winter. Pfizer says after studying over 1,200 adults who had received three vaccine doses. officials say each of their vaccines showed a substantial increase in omicron-resistant antibodies. Based on these data, we believe we have two very strong omicron- adapted candidates. , statement from Pfizer CEO Albert Bourla, via NBC News. Pfizer's tweaked shot shows a 9 to 11-fold increase in omicron-fighting antibodies. almost 1.5 times higher than the company's initial dose

Credit: Wibbitz Top Stories    Duration: 01:30Published
FDA To Pull Juul E-Cigarettes off US Market [Video]

FDA To Pull Juul E-Cigarettes off US Market

FDA To Pull Juul E-Cigarettes , off US Market. Fox News and other outlets report that the Food and Drug Administration (FDA) is gearing up to order Juul Labs Inc. to remove its e-cigarettes from store shelves in America. Fox News and other outlets report that the Food and Drug Administration (FDA) is gearing up to order Juul Labs Inc. to remove its e-cigarettes from store shelves in America. The announcement is expected to come as data presented by Juul has been under review for nearly two years. . The announcement is expected to come as data presented by Juul has been under review for nearly two years. . Fox News reports that four years ago, the vaping company came under fire for its fruity flavors and marketing direction. Fox News reports that four years ago, the vaping company came under fire for its fruity flavors and marketing direction. Fox News reports that four years ago, the vaping company came under fire for its fruity flavors and marketing direction. Critics say underage vaping surged as a result. Juul has since cut back on its marketing, and in 2019, the company stopped selling fruity, sweet cartridge flavors. . Still, sales have dramatically declined for the e-cigarette manufacturer. . The sale of all fruity e-cigarette flavors has since been banned by the FDA. Juul's impending departure would pave the way for Reynolds American Inc. and NJOY Holidings Inc. to corner the tobacco-flavored segment of the e-cigarette market. Juul's impending departure would pave the way for Reynolds American Inc. and NJOY Holidings Inc. to corner the tobacco-flavored segment of the e-cigarette market. Juul's impending departure would pave the way for Reynolds American Inc. and NJOY Holidings Inc. to corner the tobacco-flavored segment of the e-cigarette market. Fox News reports Juul will be able to file an appeal through the FDA, take the matter to court or file a new application with revised products. . Fox News reports Juul will be able to file an appeal through the FDA, take the matter to court or file a new application with revised products.

Credit: Wibbitz Top Stories    Duration: 01:30Published
FDA Panel Endorses COVID Vaccines for Children Under 5 [Video]

FDA Panel Endorses COVID Vaccines for Children Under 5

FDA Panel , Endorses COVID Vaccines, for Children Under 5. On June 15, an advisory panel to the United States Food and Drug Administration voted to recommend two COVID-19 vaccines for kids ages 5 and under. Yahoo reports that both Pfizer/BioNTech and Moderna were under review by the panel. . The unanimous FDA panel vote is the first step in what is predicted to be a quick authorization process. According to Yahoo, data from trials shows that both vaccines continue to protect against severe disease, hospitalization and death. According to Yahoo, data from trials shows that both vaccines continue to protect against severe disease, hospitalization and death. Yahoo reports that parents now have two options for how to vaccinate their children. Pfizer's vaccine for kids is delivered in three, three-microgram doses, while Moderna's vaccine is delivered in two shots of a 25-microgram dose. Our robust clinical study shows that three doses can provide protection for the circulating Omicron variant and offers promise for protection against potential future waves of COVID-19, Dr. Bill Gruber, Pfizer's Vaccine Clinical Research and Development head, via Yahoo. Our robust clinical study shows that three doses can provide protection for the circulating Omicron variant and offers promise for protection against potential future waves of COVID-19, Dr. Bill Gruber, Pfizer's Vaccine Clinical Research and Development head, via Yahoo. The committee’s support today is imperative to providing a critical tool for pediatricians, parents, and caregivers who eagerly await an option for children under five, Dr. Bill Gruber, Pfizer's Vaccine Clinical Research and Development head, via Yahoo. Both companies are now awaiting approval from the FDA and the CDC which will hold an advisory committee meeting on the topic over the weekend.

Credit: Wibbitz Top Stories    Duration: 01:30Published
Pfizer's COVID Vaccine for Kids Under 5 Moves Closer to FDA Approval [Video]

Pfizer's COVID Vaccine for Kids Under 5 Moves Closer to FDA Approval

Pfizer's COVID Vaccine for Kids Under 5 , Moves Closer to FDA Approval . Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. Pfizer announced on June 1 that its application to the Food and Drug Administration (FDA) for the vaccine was complete. The three-dose vaccine is for children between the ages of six months and five years. Pfizer released a statement detailing the application. Pfizer and BioNTech completed a rolling application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA)... , Pfizer Statement, via ABC News. ... of the 3-µg [microgram] dose of the Pfizer-BioNTech COVID-19 Vaccine.., Pfizer Statement, via ABC News. ... for children 6 months through 4 years of age (also referred to as 6 months to under 5 years of age) on June 1, 2022, Pfizer Statement, via ABC News. Pfizer reported an 80 percent effectiveness rate in children in May. The FDA also released a statement on June 1, confirming that the agency had accepted the Pfizer application. We recognize parents are anxious to have their young children vaccinated against COVID-19... , FDA Statement, via ABC News. ... and while the FDA cannot predict how long its evaluation of the data and information will take, , FDA Statement, via ABC News. ... we will review any EUA request we receive as quickly as possible using a science-based approach, FDA Statement, via ABC News. According to a poll conducted by the Kaiser Family Foundation in April of this year. ... just 18 percent of parents intend to have their children vaccinated once the vaccine is approved. 27 percent of parents stated that they will "definitely not" vaccinate their children against COVID

Credit: Wibbitz Top Stories    Duration: 01:31Published

Covaxin Covaxin Vaccine against COVID-19

Corbevax being considered as booster dose for Covishield, Covaxin jabbed people

NTAGI is considering using Corbevax as a booster vaccination against Covid-19.
DNA

Allowing Corbevax as booster for those vaccinated with Coivishield, Covaxin likely to be considered by NTAGI

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed..
IndiaTimes
Bharat Biotech’s Covaxin safe for children of  2to18 years says Lancet Journal Oneindia News*News [Video]

Bharat Biotech’s Covaxin safe for children of 2to18 years says Lancet Journal Oneindia News*News

The manufacturers of the Covid-19 vaccine Covaxin, Bharat Biotech have said that their vaccine is safe for use on children between the age group of 2 to 18 years. #Covaxin #BharatBiotech #LancetJournal

Credit: Oneindia    Duration: 01:41Published
COVAXIN BOOSTER DOSE: EFFECTIVE AGAINST OMICRON AND DELTA VARIANT| OneIndia News* News [Video]

COVAXIN BOOSTER DOSE: EFFECTIVE AGAINST OMICRON AND DELTA VARIANT| OneIndia News* News

ICMR and Bharat biotech has found in a study that Covaxin booster dose is highly effective against delta and omicron variants. Lung disease, virus shedding and are reduced after the third dose of Covaxin. #covidupdate #covaxin #boosterdose

Credit: Oneindia    Duration: 01:41Published

Bharat Biotech Bharat Biotech Indian multinational biotechnology company and vaccine manufacturer


COVID-19 COVID-19 Contagious disease caused by SARS-CoV-2

Covid 4th wave: India reports 16,103 new cases and 31 deaths in 24 hours

Covid in India: The active cases now increased to 1,11,711, as per the Union Health Ministry data updated on Sunday.
DNA

Centre grants financial aid to families of 35 journalists who died of Covid

The committee has approved total assistance of Rs 1.81 Cr during the meeting.
DNA
Covid-19 update: India logs 17,092 new cases and 29 deaths in last 24 hours | Oneindia News *news [Video]

Covid-19 update: India logs 17,092 new cases and 29 deaths in last 24 hours | Oneindia News *news

According to the Union Health ministry's data, India added 17,092 Covid cases and 29 Covid-related deaths in the last 24 hours. #CovidIndia #Covid19 #CovidCases #CoronaDeaths

Credit: Oneindia    Duration: 01:07Published

India reports 17,092 new Covid cases, 29 deaths in last 24 hours

India registered 17,092 new coronavirus infections in the last 24 hours, taking the total tally of Covid-19 infections from the beginning of the pandemic to..
IndiaTimes

Hyderabad Hyderabad Capital of Telangana, India

"Politics is a circus for KCR family": Smriti Irani slams CM for not receiving PM Modi at Hyderabad Airport

Addressing a press conference in Hyderabad, Irani said that the chief minister (KCR) has insulted both an individual and an institution.
DNA

BJP becoming stronger in Telangana, TRS scared of losing chair: G Kishan Reddy

Union minister G Kishan Reddy on Saturday said that Telangana Rashtra Samithi (TRS) is scared of BJP because the party is becoming stronger in BJP Telangana and..
IndiaTimes

Mission Telengana: BJP key meet in Hyerabad from today

With its slogan 'Saalu dora, selavu dora (enough sir, goodbye sir)' targeting Telangana CM K Chandrashekar Rao, BJP will hold its two-day national executive..
IndiaTimes

BJP eyes big push in Telangana as its national executive meets in Hyderabad

BJP president J P Nadda also held a road show after his arrival in the city, which is hosting the party's national executive after 18 years.
DNA

BJP national executive meet to start tomorrow, PM Modi to attend all sessions

The two-day NEC meeting of Bharatiya Janta Party will be chaired by party chief J P Nadda in Hyderabad.
DNA

Related videos from verified sources

Under the Wire - Dr Phillip Altman on Clinical Trial and COVID [Video]

Under the Wire - Dr Phillip Altman on Clinical Trial and COVID

Dr Altman is a well-known Australian authority on clinical trials and regulatory affairs with more than 40 years of experience in designing, managing and reporting of clinical trials and in working..

Credit: Rumble     Duration: 00:30Published